scholarly journals Letter to the editor concerning ‘Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA’

2015 ◽  
Vol 26 (5) ◽  
pp. 1033-1034 ◽  
Author(s):  
J. Foglietta ◽  
G. Metro ◽  
L. Crinò ◽  
S. Gori
Keyword(s):  
Breast Cancer ◽  
Central Nervous System ◽  
Nervous System ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Exploratory Analysis ◽  
Trastuzumab Emtansine ◽  
Her2 Positive ◽  
Letter To The Editor ◽  
Central Nervous System Metastases

scholarly journals Effect of Central Nervous System Metastases on Treatment Discontinuation and Survival in Older Women Receiving Trastuzumab for Metastatic Breast Cancer

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Mark D. Danese ◽  
Karla Lindquist ◽  
Justin Doan ◽  
Deepa Lalla ◽  
Melissa Brammer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Central Nervous System ◽  
Nervous System ◽  
Metastatic Breast Cancer ◽  
Proportional Hazards ◽  
Metastatic Breast ◽  
Cns Metastases ◽  
Her2 Positive ◽  
Time To Death ◽  
Risk Of Death

Background. Trastuzumab improves survival in HER2-positive women with metastatic breast cancer (MBC). The consequences of longer survival include a higher likelihood of additional metastases, including those in the central nervous system (CNS). The effect of CNS metastases on both trastuzumab discontinuation and survival in older patients has not been described.Patients and Methods. We used the Surveillance Epidemiology and End Results (SEER) Medicare data to identify a cohort of 562 women age 66 or older with MBC who were diagnosed between January 1, 2000 and December 31, 2005, free of CNS metastases, and initiated trastuzumab after MBC diagnosis. Time to discontinuation and time to death were analyzed using proportional hazards models.Results. Newly diagnosed CNS metastases were associated with both higher risk of trastuzumab discontinuation (relative hazard[RH]=1.78, 95% CI 1.11–2.87) and higher risk of death (RH=2.49, 95% CI 1.84–3.37). The incidence rate of new CNS metastases was comparable among various sites of metastasis (10.7 to 14.7 per 1,000 patient-months), except for bone which was higher (24.1 per 1,000).Conclusion. The diagnosis of CNS metastases was associated with an increase in both the likelihood of discontinuing trastuzumab therapy as well as the risk of death.

scholarly journals Glycoprotein M6A (GPM6A) is over-expressed in brain metastatic breast cancer.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Central Nervous System ◽  
Nervous System ◽  
Metastatic Breast Cancer ◽  
Microarray Data ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Significant Differential Expression ◽  
Central Nervous System Metastases ◽  
The Brain

One study reported the incidence of central nervous system metastases in breast cancer patients treated with trastuzumab as 34% (1). We mined published microarray data (2, 3) to discover genes associated with brain metastasis in breast cancer. We identified significant differential expression of glycoprotein M6A, encoded by GPM6A (4, 5), in the brain metastases of patients with metastatic breast cancer. GPM6A may be relevant to the biology underlying colonization of the brain with metastatic breast cancer clones.

Sign in / Sign up

Export Citation Format

Share Document